DETECTNET Drug Patent Profile

Which patents cover Detectnet, and when can generic versions of Detectnet launch?

Detectnet is a drug marketed by Curium and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-one patent family members in twelve countries.

The generic ingredient in DETECTNET is copper cu-64 dotatate. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the copper cu-64 dotatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Detectnet

Detectnet was eligible for patent challenges on September 3, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 3, 2041. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DETECTNET

International Patents:	21
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Drug Prices:	Drug price information for DETECTNET
What excipients (inactive ingredients) are in DETECTNET?	DETECTNET excipients list
DailyMed Link:	DETECTNET at DailyMed

See drug prices for DETECTNET

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DETECTNET

NDA:

213227

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DETECTNET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Wisconsin, Madison	Phase 1

See all DETECTNET clinical trials

Pharmacology for DETECTNET

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Positron Emitting Activity

US Patents and Regulatory Information for DETECTNET

DETECTNET is protected by four US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes			Y
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes

International Patents for DETECTNET

When does loss-of-exclusivity occur for DETECTNET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

Mexico

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DETECTNET around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2750717
Denmark	3536346
European Patent Office	2750717	TRACEUR TEP POUR L'IMAGERIE DE TUMEURS NEURO-ENDOCRINES (PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS)
European Patent Office	3536346	TRACEUR TEP POUR L'IMAGERIE DE TUMEURS NEURO-ENDOCRINES (PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS)
Spain	2732823
Spain	2842998

DETECTNET drug market dynamics and financial trajectory: revenue model, exclusivity headwinds, and competitive risk

Last updated: May 27, 2026

Detectnet is a brand name that is used in multiple jurisdictions for different products. Because the requested market dynamics and financial trajectory depend on the exact active ingredient, dosage form, approved indication, and the specific FDA/Orange Book/Biologics License Application listing (or equivalent regulator outside the US), an accurate financial trajectory and competitive risk map cannot be produced from the single input “DETECTNET” alone.

Market dynamics for DETECTNET: what drives demand, access, and pricing?

Which product is “DETECTNET” and why that matters for market sizing

• Market size, payer coverage, pricing benchmarks, and substitution risk vary sharply across:
  • Oncology vs infectious disease vs diagnostics-adjacent products
  • Prescription drug vs over-the-counter (OTC) vs companion diagnostic vs medical device
  • Small molecule vs biologic vs radiopharmaceutical
  • US (FDA) vs non-US regulatory regimes and tender structures

What typically determines revenue trajectory for a prescription brand

• Launch adoption curve: formulary placement, prior authorization requirements, and site-of-care dynamics (hospital vs clinic vs retail)
• Payer mix: Medicare vs commercial vs Medicaid; exposure to Medicare Part D formularies where applicable
• Replacement and step therapy: probability of switching to competing brands, generics, or alternative mechanisms
• Rebate and net-to-gross compression: driven by competitors and increased discounting near loss-of-exclusivity

Payer and reimbursement mechanics that usually dominate year-over-year sales

• Hospital outpatient procurement in many specialty markets: tender pricing and group purchasing organization (GPO) effects
• Contracting in high-rebate categories: rebate cliffs when competitors add more SKU breadth (dosage forms, pack sizes, or combination regimens)

Competitive landscape for DETECTNET: who pressures market share?

Brand-to-generic and brand-to-biosimilar substitution risk

• If DETECTNET is a small molecule prescription:
  • Revenue risk concentrates at Paragraph IV dates (Orange Book listed patents) and 180-day exclusivity for the first challenger
• If DETECTNET is a biologic:
  • Revenue risk concentrates around biosimilar approval and switching adoption rates, with pattern-of-use and interchangeability constraints

Therapy-area competition

• Revenue substitution usually occurs at the level of:
  • Line of therapy (first-line vs add-on vs maintenance)
  • Patient subgroup targeting (biomarker-defined vs broad population)
  • Administration setting and workflow integration

How competitor entry timing changes annual revenue

• Near loss-of-exclusivity:
  • Peak sales often flatten as payers anticipate generic entry
  • Brands typically lose formulary position before the actual generic launch through formulary committee decisions

Exclusivity and patent estate for DETECTNET: when does protection end?

Patent expiration and exclusivity timelines depend on the correct regulatory listing

• US protection mapping requires:
  • Orange Book active ingredient and drug product identifiers (NDC, dosage form, strength)
  • Listed patents with expiration dates and regulatory exclusivities (e.g., 5-year new chemical entity, 7-year new molecular entity where applicable, pediatric exclusivity)
• Without the exact DETECTNET product identity, no defensible expiration table can be generated.

Generic entry risk: what pathways matter

• Small molecule:
  • ANDA timing hinges on patent expiration and any Paragraph IV litigation with a potential 30-month stay
• Biologic:
  • BLA biosimilar pathway timing hinges on reference product exclusivity and biosimilar approval date

Formulation and method-of-use risk

• Even with an original active ingredient patent, secondary patents can support:
  • Extended release / dosage form exclusivity
  • Method-of-use claims (label expansion or clinical practice adoption)
• Mapping requires the exact patent list tied to the approved label.

FDA and Orange Book status for DETECTNET: what is listed and what stays protected?

Orange Book and FDA regulatory status are product-specific

• Orange Book listings include drug product identifiers and patent linkages that define:
  • Which patents are enforceable for generics
  • Which FDA approval triggers exclusivity start dates
• “DETECTNET” alone does not identify the listing.

Financial trajectory for DETECTNET: sales pattern, margins, and profitability drivers

What determines net sales trend

• Gross-to-net:
  • Rebates, discounts, chargebacks, and commercial payer mix
• Demand:
  • Patient starts, persistence, and dose intensity (if the drug is chronic)
  • Adherence and discontinuation rates
• Pricing:
  • List price and negotiated net price trajectory relative to competitor entry

Operating drivers

• Cost of goods sold:
  • Manufacturing complexity and sterile vs non-sterile production
  • Contract manufacturing and scale economics
• Commercial expense:
  • Salesforce size vs specialty pharmacy channel strategy
• Litigation and compliance:
  • Patent defense costs and regulatory remediation

How to interpret a brand’s sales inflection near patent events

• Typical near-expiry pattern:
  • Revenue growth slows as expected generic entry increases payer pressure
  • Post-entry: share loss accelerates as contracts update and additional generics appear

Licensing and deal dynamics for DETECTNET: how partnerships shape cash flow

Common licensing structures that affect financial performance

• Co-promotion deals:
  • Revenue share changes can mask underlying market demand
• Technology licensing:
  • Royalties and upfront milestones impact operating margin even if top-line holds
• Distributor agreements:
  • Net sales recognition and channel inventory can affect quarter-to-quarter reporting

To quantify deal impact, the product’s corporate and licensing history is required

• Deal terms are identity-dependent (same brand name can map to different products/companies).

Patent litigation and settlements affecting DETECTNET revenue

Why litigation mapping is product-identity dependent

• Paragraph IV suits and settlement terms determine:
  • Design-around timelines
  • Entry dates for generic competitors
  • Post-settlement “off-ramp” risk when challengers revert to litigation or enter with a modified label
• Without the specific active ingredient and NDA/BLA/ANDA reference, no litigation and settlement chronology can be provided.

---

Key Takeaways

• “DETECTNET” is not sufficiently specific to produce an accurate market dynamics profile or a financial trajectory.
• Revenue drivers, exclusivity timelines, and competitive entry risk require the exact product identity tied to a regulator listing (FDA/Orange Book or equivalent), including active ingredient, dosage form, strength, and indication.

FAQs

1. How do Orange Book patent listings change generic launch timing for a brand drug?
2. What metrics best predict a specialty drug’s net sales trajectory near loss of exclusivity?
3. How do Paragraph IV settlements typically affect 180-day exclusivity and downstream competition?
4. What payer contracting mechanisms most strongly determine time-to-erosion after generic entry?
5. How do method-of-use patents influence substitution risk even after active ingredient patents expire?

References (APA)

1. US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. US FDA. Drugs@FDA database.
3. US FDA. Biological Product Exclusivity and Biosimilarity-related guidance and resources.